论文部分内容阅读
目的 研究新辅助化疗对宫颈癌患者血清和组织中UPAR、TGF-β、CD105水平的影响及其疗效。方法 选取2015年1月~2016年2月间收治的72例宫颈癌患者为研究对象,随机分为对照组(常规放疗)36例和观察组(新辅助化疗联合放疗)36例,比较两组患者的临床总有效率、组织学有效率、治疗前后血清和组织UPAR、TGF-β、CD105的表达情况。结果观察组的临床总有效率及组织学有效率均高于对照组,血清和组织中UPAR、TGF-β、CD105的表达均低于对照组,差异均有统计学意义(P<0.05)。结论 新辅助化疗对宫颈癌患者的疗效确切,可显著降低血清及组织中UPAR、TGF-β、CD105的表达,在宫颈癌治疗中具有应用价值。
Objective To investigate the effect of neoadjuvant chemotherapy on the serum and tissue levels of UPAR, TGF-β and CD105 in patients with cervical cancer and its efficacy. Methods Seventy-two patients with cervical cancer who were treated between January 2015 and February 2016 were selected and randomly divided into control group (conventional radiotherapy) 36 cases and observation group (neoadjuvant chemotherapy combined radiotherapy) 36 cases. The patient’s total clinical efficiency, histological efficiency, serum and tissue before and after treatment UPAR, TGF-β, CD105 expression. Results The total clinical effective rate and histological effective rate in observation group were higher than those in control group. The expression of UPAR, TGF-β and CD105 in serum and tissue were lower than those in control group (P <0.05). Conclusion Neoadjuvant chemotherapy is effective in treating patients with cervical cancer, and can significantly reduce the expression of UPAR, TGF-β and CD105 in serum and tissue, and has value in the treatment of cervical cancer.